<DOC>
	<DOCNO>NCT01947803</DOCNO>
	<brief_summary>The purpose study evaluate safety treatment response paliperidone palmitate administer Chinese patient schizophrenia .</brief_summary>
	<brief_title>A Safety Effectiveness Study Paliperidone Palmitate Chinese Patients With Schizophrenia</brief_title>
	<detailed_description>This study single-group , open-label ( name study drug know patient ) , multicenter study evaluate safety efficacy/treatment response paliperidone palmitate administer 25 week once-monthly injection Chinese patient schizophrenia previously receive treatment oral antipsychotic medication . A target 353 patient ( inpatient outpatient ) schizophrenia enrol study receive injection study drug ( paliperidone palmitate ) Days 1 8 , thereafter monthly flexible dose , base patient ' tolerability and/or efficacy . The study consist screen period 1 week treatment , 25-week treatment period , follow-up period approximately 30 day last injection study drug . Upon meet entry criterion study , patient receive total 8 intramuscular ( IM ) injection paliperidone palmitate treatment period follow : 150 mg equivalent ( eq ) Day 1 , 100 mg eq Day 8 , subsequent monthly IM injection flexible dose range 75-150 mg eq . If patient report sign symptom worsen schizophrenia , investigator may prescribe rescue medication ( quick-relief fast-acting medication usually work right away relieve symptom ) lorazepam ( antianxiety drug ) control agitation , irritability , restlessness , hostility . Safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Signed informed consent participate study obtain Confirmation diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) within 5 year prior screen Patient willing able fill selfadministered questionnaire study confirmation patient give adequate dose appropriate oral antipsychotic adequate period time enrollment , previous treatment consider unsuccessful due one follow reason : lack efficacy , lack tolerability safety , lack compliance and/or reason switch another antipsychotic medication The patient 's psychiatric diagnosis due direct pharmacological effect drug abuse substance medication , due general medical condition ( eg , clinically notable hypothyroidism ) The patient treatment resistant judgment investigator The patient meet DSMIV definition substance dependence ( except nicotine caffeine ) within 6 month prior entry The patient previously define hypersensitivity ( anaphylaxistype reaction ) risperidone paliperidone excipients The patient receive treatment longacting injectable antipsychotic within 3 injection cycle prior baseline , receive clozapine within 3 month prior screen , receive treatment investigational agent within 30 day screen visit , participate one investigational drug study past 12 month , plan use investigational drug time frame study History current symptom tardive dyskinesia , history neuroleptic malignant syndrome , evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal , neurological , endocrine , metabolic pulmonary disease past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Safety</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Chinese</keyword>
</DOC>